Research on the safety and efficacy of telitacicept in the treatment of IgA nephropathy in children.

This study retrospectively evaluated telitacicept in ten pediatric IgA nephropathy patients with proteinuria (24-hour urinary protein: 23.97 ± 26.63 mg/kg). All patients received steroid therapy, and half received combined immunosuppressants. After a median follow-up of 3.75 months, eight patients achieved proteinuria remission (four complete, four partial). Steroid reduction (33.3-92%) occurred in six patients, and four discontinued steroids entirely. Key clinical outcomes included improvements in protein excretion. Adverse events were mild, including injection-site reactions (2 cases), upper respiratory infection (1 case), rash (1 case), and leukopenia (1 case), with no severe events reported. Telitacicept appears effective and safe for reducing proteinuria and steroid use in pediatric IgAN.